Apparatus and method for control of tissue/implant interactions
First Claim
1. An implant having a tissue/implant interface, comprising an implant having an outer surface;
- a bioactive polymer layer adjacent to at least a portion of the outer surface; and
controlled release nanoparticles, liposomes, or microspheres containing a tissue response modifier, wherein the controlled release nanoparticles, liposomes, or microspheres provides the tissue response modifier to the site of implantation in a quantity effective to control tissue response at the site of implantation.
4 Assignments
0 Petitions
Accused Products
Abstract
A tissue/implant interface, comprising an implant and a bioactive polymer layer adjacent at least a portion of the outer surface of the implant, wherein the polymer layer contains at least one tissue response modifier covalently attached to the polymer layer or entrapped within the polymer layer in a quantity effective to control the tissue response at the site of implantation. Preferably, the at least one tissue response modifier controls inflammation, fibrosis, and/or neovascularization. Exemplary tissue response modifiers include, but are not limited to, steroidal and non-steroidal anti-inflammatory agents, anti-fibrotic agents, anti-proliferative agents, cytokines, cytokine inhibitors, neutralizing antibodies, adhesive ligands, and combinations thereof. Use of the various combinations of tissue response modifiers with bioactive polymers provides a simple, flexible and effective means to control the implant/tissue interphase, improving implant lifetime and function.
-
Citations
37 Claims
-
1. An implant having a tissue/implant interface, comprising
an implant having an outer surface; -
a bioactive polymer layer adjacent to at least a portion of the outer surface; and
controlled release nanoparticles, liposomes, or microspheres containing a tissue response modifier, wherein the controlled release nanoparticles, liposomes, or microspheres provides the tissue response modifier to the site of implantation in a quantity effective to control tissue response at the site of implantation. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 28, 29, 30)
-
-
26. The implant of claim 26, wherein the controlled release microspheres comprise a mixture of standard and predegraded microspheres.
- 31. A controlled release delivery system, comprising a mixture of predegraded and untreated microspheres.
Specification